An observational study in COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation Chronic Obstructive Pulmonary Disease and Muscle Oxygenation, sponsored by Hacettepe University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Hacettepe University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University — 10 open to participants now, 12 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Hacettepe University.
Among the 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2026, is one of 12 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 18th registered.
5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →10 of the 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University are open now, in 1 country. Recruiting first, the newest first:
Hacettepe University · Sites in Turkey
Ages 40+ · Healthy volunteers
Hacettepe University · Sites in Turkey
Ages 40+ · Healthy volunteers
Hacettepe University · Sites in Turkey
Ages 40+
Hacettepe University · Sites in Turkey
Ages 40–65 · Healthy volunteers
Hacettepe University · Sites in Turkey
Ages 40+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 40 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 42 across the 6 interventional studies, 45 across the 12 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hacettepe University is the lead sponsor of 1,009 studies on the registry; 214 are open to participants now.
2 of the studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06497816Hacettepe UniversityHealth Literacy, Physical and Cognitive Function, Health-related Behaviors, and Quality of Life in COPD | 2027-06-15 |
| NCT07801547Hacettepe UniversityMuscle Oxygenation in Patients With COPD Exacerbation | 2027-10-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) is often complicated by acute exacerbations, which lead to functional impairments, increased dyspnea, and a rapid decline in lung function. During an exacerbation, impaired pulmonary gas exchange, systemic inflammation, and increased work of breathing significantly alter oxygen availability and metabolic demand in skeletal muscles. The aim of this study is to evaluate and compare respiratory and peripheral muscle oxygenation in patients with acute exacerbation of COPD (AECOPD) and patients with clinically stable COPD. By examining these physiological changes, the study seeks to determine the impact of exacerbations on muscle function and oxygenation efficiency
Chronic obstructive pulmonary disease (COPD) is characterized by recurrent acute exacerbations that negatively affect patients' quality of life and accelerate lung function decline. Severe exacerbations requiring hospitalization pose a significant mortality risk both during admission and in the following year.
During acute exacerbations, maximal pressure generation by respiratory muscles declines, and respiratory muscle efficiency-particularly of the diaphragm-is significantly reduced. Acute dynamic hyperinflation further shortens the inspiratory muscles, leading to functional muscle weakness. Consequently, accessory respiratory muscles are recruited maximally, often causing notable alterations in chest-wall and abdominal kinematics. Due to the requirement of spending a higher proportion of their maximum capacity with each breath, these patients face an elevated risk of developing respiratory muscle fatigue. Exacerbations lead to severe hypoxemia caused by impaired pulmonary gas exchange, driven primarily by ventilation-perfusion mismatch and increased tissue oxygen consumption. Acute hypoxemia exacerbates muscle weakness and impairs skeletal muscle function. Even after discharge from respiratory intensive care units following severe exacerbations, persistent respiratory muscle dysfunction is observed in more than a third of patients, requiring additional care and rehabilitation.
Physiological factors such as impaired gas exchange, reduced perfusion, and systemic inflammation during exacerbations substantially impact muscle oxygenation. Reduced arterial oxygen content diminishes oxygen availability to peripheral tissues and muscles. Simultaneously, the metabolic demands of both respiratory and peripheral muscles increase due to the heightened work of breathing and systemic stress.
This study aims to investigate respiratory and peripheral muscle oxygenation in patients with AECOPD and stable COPD, evaluating underlying physiological changes and assessing the impact of exacerbations on muscle function and oxygenation dynamics.
The aim of study is to investigate respiratory and peripheral muscle oxygenation in patients with AECOPD.
The study population consists of adult patients aged 40 years and older diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD guidelines. The sample includes two distinct cohorts: patients admitted or presenting with an acute exacerbation of COPD (AECOPD), and patients in a clinically stable period (GOLD Grades 1-4) without exacerbations in the preceding 4 weeks.
Inclusion Criteria:
Acute Exacerbation Group: 1. Diagnosis of (COPD) 2. Hospital admission or presentation due to an acute exacerbation of COPD 3. Age 40 years or older 4. Voluntary agreement to participate with signed written Clinically Stable Group: 1. Diagnosis of COPD (GOLD Stage 1, 2, 3, or 4) 2. Age 40 years or older 3. Clinically stable condition for at least the past 4 weeks without acute exacerbations 4. Voluntary agreement to participate with signed written informed consent
Exclusion Criteria: Acute Exacerbation Group: 1. Active participation in a formal pulmonary rehabilitation program 2. Co-existing neurological disorders 3. Heart failure classified as (NYHA) Class III or IV 4. Unstable mental or cognitive status ( [MMSE] score ≤24) 5. History of surgical intervention within the past three months 6. Presence of malignant conditions .
Clinically Stable Group: 1. History of lung cancer, sarcoidosis, tuberculosis, and/or prior lung surgery 2. Known mental or cognitive impairment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
acute exacerbation of COPD
clinically stable without any acute exacerbations for at least the past 4 weeks.
Muscle Oxygen Saturation
Muscle oxygen saturation (SmO\_2) will be measured continuously using Near-Infrared Spectroscopy (NIRS) (Train.Red FYER) on the intercostal, deltoid, and dominant quadriceps muscles. The primary parameter ΔSmO\_2 max represents the difference between the peak SmO\_2 during functional tasks (30-second sit-to-stand test, 4-meter gait speed test, and upper extremity assessment) and the baseline resting
Time frame: baseline (1 day)
functional capacity
30-Second Sit-to-Stand Test: Assesses functional lower-limb muscle strength and exercise capacity. The total number of completed full stand-ups from a chair (height 43.2 cm) within 30 seconds will be recorded.
Time frame: baseline (1 day)
Gait speed
4-Meter Gait Speed Test: Gait speed will be evaluated over a 4-meter course at normal walking pace. Gait speed is calculated in meters per second (m/s) by dividing 4 meters by the time taken
Time frame: baseline (1 day)
Peripheral Muscle Strength
Maximal isometric handgrip strength will be measured in kilograms (kg) using a digital hand dynamometer (Baseline BIMS). The highest value of three trials for both dominant and non-dominant hands will be recorded
Time frame: baseline (1 day)
pulmonary functions
Spirometry will be performed according to ATS/ERS guidelines. Values will be recorded.
Time frame: baseline (1 day)
Dyspnea and Fatigue Perception
Dyspnea will be evaluated using the Modified Medical Research Council (mMRC) scale (grades 0-4) and Visual Analog Scale (VAS, 0-10 cm). Fatigue perception will be assessed using the Modified Borg Scale (0-10) before and after functional tests.
Time frame: baseline (1 day)
Activities of Daily Living
Activities of daily living will be assessed using the London Chest Activity of Daily Living (LCADL) scale (score range 0-75).
Time frame: baseline (1 day)
Start is estimated for Aug 2026; primary completion for Oct 2027, 13 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →